174 related articles for article (PubMed ID: 16383232)
1. [Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].
Wang LH; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):449-52. PubMed ID: 16383232
[TBL] [Abstract][Full Text] [Related]
2. [The heat shock protein 90 inhibitor induces apoptosis and differentiation of Kasumi-1 and its mechanisms].
Yu WJ; Rao Q; Wang M; Tian Z; Liu XR; Lin D; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):728-31. PubMed ID: 16620576
[TBL] [Abstract][Full Text] [Related]
3. [Imatinib induces c-kit positive myeloma cells apoptosis].
Li J; Huang BH; Zhao Y; Luo SK
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):230-3. PubMed ID: 18843975
[TBL] [Abstract][Full Text] [Related]
4. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
6. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
[TBL] [Abstract][Full Text] [Related]
7. [Effect of phenylbutyrate, a histone deacetylase inhibitor, on differentiation and apoptosis of Kasumi-1 cells].
Hao CL; Tang KJ; Tian Z; Xing HY; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2003 May; 24(5):241-4. PubMed ID: 12859874
[TBL] [Abstract][Full Text] [Related]
8. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
10. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
Pan J; Quintás-Cardama A; Manshouri T; Cortes J; Kantarjian H; Verstovsek S
Cancer Sci; 2007 Aug; 98(8):1223-5. PubMed ID: 17517053
[TBL] [Abstract][Full Text] [Related]
13. Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate.
Park J; Kim S; Oh C; Yoon SS; Lee D; Kim Y
Biochem Biophys Res Commun; 2005 Oct; 336(3):942-51. PubMed ID: 16157305
[TBL] [Abstract][Full Text] [Related]
14. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.
Juurikivi A; Sandler C; Lindstedt KA; Kovanen PT; Juutilainen T; Leskinen MJ; Mäki T; Eklund KK
Ann Rheum Dis; 2005 Aug; 64(8):1126-31. PubMed ID: 16014680
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
17. [Cytotoxic activities of Celecoxib on leukemic cells and the synergistic effects of Celecoxib with Imatinib thereupon].
Li RJ; Gong FJ; Zhang GS
Zhonghua Yi Xue Za Zhi; 2006 May; 86(20):1417-20. PubMed ID: 16796927
[TBL] [Abstract][Full Text] [Related]
18. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
20. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
Sambol EB; Ambrosini G; Geha RC; Kennealey PT; Decarolis P; O'connor R; Wu YV; Motwani M; Chen JH; Schwartz GK; Singer S
Cancer Res; 2006 Jun; 66(11):5858-66. PubMed ID: 16740725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
